Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Filings indexed 796 across all filing types
Latest filing 2024-12-11 Foreign Filer Report
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2024-12-11 English
PHARMING GROUP N.V.
Major Shareholding Notification
2024-11-14 English
MS INITIAL
Major Shareholding Notification
2024-11-08 English
6-K
Foreign Filer Report
2024-10-24 English
Pharming Group reports third quarter 2024 financial results and provides business update
Earnings Release Classification · 1% confidence The document is titled "Pharming Group publiceert financiële resultaten derde kwartaal 2024" (Pharming Group publishes third quarter 2024 financial results). It contains key financial highlights for Q3 2024 and the first nine months (9M 2024), including revenue, operating income, and balance sheet data comparing Q3 2024 to Q3 2023. The text explicitly states it is publishing the 'voorlopige, niet-gecontroleerde financiële verslag over de drie maanden eindigend op 30 september 2024' (preliminary, unaudited financial report for the three months ended September 30, 2024). This content structure—a comprehensive report covering a period shorter than a year with detailed financial tables—aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it mentions a conference call (CT) and CEO resignation (MANG), the primary purpose and bulk of the document is the financial reporting for the quarter. Q3 2024
2024-10-24 Dutch
Pharming Group reports third quarter 2024 financial results and provides business update
Earnings Release Classification · 1% confidence The document explicitly states it presents the "preliminary, unaudited financial report for the three months ended September 30, 2024." It contains detailed financial tables (Income Statement, Balance Sheet, Segment information) and commentary on quarterly performance, revenue drivers (RUCONEST®, Joenja®), and operational updates. This structure and content strongly indicate a comprehensive report covering a period shorter than a full year (Q3 2024). This aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it contains an organizational update about the CEO's departure, the primary focus and bulk of the document are the financial results for the nine months and the third quarter. Q3 2024
2024-10-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.